Join Dr. Adam Robinson for a virtual home study presentation discussing emerging new drug approvals and therapeutics surrounding chimeric antigen receptor CAR T-cell therapies in relapsed or refractory multiple myeloma. This presentation will further explore the preliminary efficacy and safety data surrounding some of the agents currently being studied. To learn more about this specific activity, including speaker information and learning objectives, expand the module below (click the +). Pharmacists can earn .75 contact hours of knowledge-based home study CE credit at the completion of this activity.
St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To learn more about the specific program information, including universal activity numbers (UAN's) and learning objectives, please expand the modules below. Following successful completion of an evaluation, CE credit will be automatically reported to NABP through the CPE Monitor system, using the NABP ePID numbers and date of birth (MMDD) stored in participants' user profiles. Follow this link to learn more about CPE Monitor and the credit reporting process » Participants are responsible for ensuring receipt of credit; no credit can be corrected or awarded if more than 60 days have passed from the date of the event or if the home study is expired.
It is the policy of St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in this program are expected to disclose to the program audience any real or apparent conflicts of interest related to the content of the presentation.
Requirements for CE Credit
To claim credit for these sessions, participants must complete the following for each session (with a unique UAN):
- Visit this site. Make sure you are logged in and registered before proceeding.
- Complete an evaluation by clicking the green evaluation button for each session/block.
- Enter the evaluation code that was given to you at the end of the session you attended.
- Answer all questions honestly - we appreciate your feedback! All responses are stored anonymously.
- Click submit. As soon as you submit, a report containing the NABP ePID and DOB stored in your profile will be automatically sent to CPE Monitor.
- Please allow up to 48 hours for processing. Your credit should appear in your NABP profile online.
If you experience difficulty, please contact our office so that we may assist you. We are happy to help!
For simultaneous sessions, participants should claim credit ONLY for those sessions they attended and ignore those they did not attend. Attendance will be reconciled against sign-in sheets. Those sessions not attended will be removed from the participants' profiles after the conclusion of the conference. Participants are responsible for ensuring accuracy of credit reporting and receipt of credit. It is recommended that participants log on and reivew the information under "my account" prior to submitting the evaluation. NABP ePID and date of birth must be accurate for credit reporting to occur. Evaluations cannot be reopened after 14 days.
Participants are encouraged to check their NABP eProfiles for receipt of credit within one week of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact our office as soon as possible. To best comply with ACPE's CE credit reporting policy, St. Louis College of Pharmacy at UHSP is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
Learn more! Click the + symbol to expand.
The treatment armamentarium for multiple myeloma has significantly expanded in the past decade, with various new drug approvals and therapeutic targets. These approvals have improved prognosis and survival of patients with multiple myeloma, though relapse is still common. Multiply-relapsed disease carries a poor prognosis, and there is a need for new therapies and novel therapeutic targets. Given success in other malignancies, chimeric antigen receptor (CAR) T-cell therapy is currently under investigation as a means to improve outcomes for patients for patients with multiply relapsed disease. Relatively few pharmacists have encountered these agents in clinical practice or have been exposed to preliminary data surrounding their use. This seminar will attempt to provide education surrounding CAR T-cell therapies in relapsed or refractory multiple myeloma and preliminary efficacy and safety data surrounding some of the agents currently being studied.
- Describe attributes of B-cell maturation antigen (BCMA) that make it a viable chimeric antigen receptor (CAR) T-cell target.
- Identify advantages of CAR T-cell therapy in relapsed and refractory multiple myeloma (R/R MM).
Adam Robinson, Pharm.D.
Release Date: Feb 2, 2021
Credit Expiration Date: Feb 2, 2024